Quantcast

Latest Eisai Co. Ltd. Stories

2014-03-31 04:20:57

WOODCLIFF LAKE, N.J., March 31, 2014 /PRNewswire/ -- Eisai Inc., a subsidiary of Tokyo-based Eisai Co., Ltd., today announced the sale and assignment of its rights to a worldwide exclusive license for DACOGEN(®) (decitabine) for Injection to Otsuka Pharmaceutical Co., Ltd., giving Otsuka full development and commercialization rights for the product in the former Eisai territories of the United States, Canada and Japan. Eisai will retain its rights for DACOGEN(®) in Mexico. In...

2014-03-20 12:32:40

JOINT RESEARCH PROJECT AWARDED GHIT FUND GRANT TOKYO, March 20, 2014 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito, "Eisai?") announced today that it has entered a collaboration with the Liverpool School of Tropical Medicine (Liverpool, United Kingdom, ?"LSTM?") and University of Liverpool (Liverpool, United Kingdom, ?"UoL") to jointly identify new drugs effective against lymphatic filariasis and onchocerciasis (river blindness), both major...

2014-03-11 12:29:05

LONDON, March 11, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report:Alzheimer's Disease Therapeutics and Diagnostics: World Market 2013-2023 Report DetailsAlzheimer's medicine - your guide to technologies, trends and revenuesWhere's treatment of Alzheimer's disease heading? Visiongain's new report gives you revenue predictions for those drugs and diagnostic tests from 2013, helping you stay ahead.There you find financial data, R&D trends,...

2014-03-10 08:30:23

Company Appoints New Executive Leaders WOODCLIFF LAKE, N.J., March 10, 2014 /PRNewswire/ -- Eisai Inc., a subsidiary of Tokyo-based Eisai Co., Ltd., today announced the appointments of Yuji Matsue as chairman and chief executive officer and Shaji Procida as president and chief operating officer, effective April 1, 2014. Mr. Matsue and Ms. Procida succeed current President and CEO Lonnel Coats, who will be retiring from Eisai in June 2014 after 18 years. Over the next few months,...

2014-02-03 04:20:02

Tokyo, Feb 3, 2014 - (JCN Newswire) - Eisai Co., Ltd. announced today that it will launch the vascular embolization device DC Bead(R) (specially controlled medical device) in Japan on February 4.DC Bead contains hydrophilic microspheres made from cross-linked polyvinyl alcohol polymer. Developed by Biocompatibles UK Limited (Biocompatibles), a BTG International group company, as an intravascular embolization device, it is injected via catheter into targeted blood...

2014-01-22 12:23:39

LONDON, Jan. 22, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report:Pharmerging Markets 2012-2016TechNavio's analysts forecast the Pharmerging market to grow at a CAGR of 12.44 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increase in healthcare spending. The Pharmerging market has also been witnessing an increase in partnerships among vendors. However, the price pressure could pose a challenge to the...

2013-10-16 23:23:04

Reportbuyer.com just published a new market research report: Alzheimer’s Disease Therapeutics and Diagnostics: World Market 2013-2023. London (PRWEB) October 16, 2013 Alzheimer's medicine - your guide to technologies, trends and revenues Where's treatment of Alzheimer's disease heading? Visiongain's new report gives you revenue predictions for those drugs and diagnostic tests from 2013, helping you stay ahead. There you find financial data, R&D trends, opportunities,...


Word of the Day
negawatt
  • A unit of saved energy.
Coined by Amory Lovins, chairman of the Rocky Mountain Institute as a contraction of negative watt on the model of similar compounds like megawatt.